Group 1: Voya MidCap Opportunities Fund Overview - The Voya MidCap Opportunities Fund's Q4 2025 investor letter highlights solid market gains but notes relative underperformance against the Russell Mid Cap Growth Index due to unfavorable stock selection [1] - The fund managers maintain a cautiously constructive outlook, emphasizing the importance of active and flexible positioning amid ongoing geopolitical risks and policy uncertainty [1] - The letter indicates that broadening market leadership, sustained corporate capital expenditure, and AI-led innovation could support future returns [1] Group 2: Vera Therapeutics, Inc. Performance - Vera Therapeutics, Inc. was a top contributor to the fund's performance in Q4 2025, driven by positive phase three clinical trial results for its kidney disease treatment [3] - At the end of Q4 2025, Vera Therapeutics represented 0.93% of the fund's portfolio, with a one-month return of -9.09% and a trading range of $18.53 to $56.05 over the past 52 weeks [2] - As of January 22, 2026, Vera Therapeutics' stock closed at approximately $45.77 per share, with a market capitalization of about $3.249 billion [2] Group 3: Hedge Fund Interest and Market Position - Vera Therapeutics was held by 36 hedge fund portfolios at the end of Q3 2025, a decrease from 40 in the previous quarter [4] - The investment community acknowledges the risks and potential of Vera Therapeutics but expresses a stronger conviction in AI stocks for higher returns in a shorter timeframe [4]

Core Viewpoint - Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank 1 (Strong Buy) due to a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years, indicating a company's earnings outlook [1][2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [4][6]. Recent Developments for Akebia Therapeutics - Akebia Therapeutics has seen a 65.4% increase in the Zacks Consensus Estimate over the past three months, with expected earnings of -$0.05 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. - The upgrade to Zacks Rank 1 places Akebia in the top 5% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term due to improved earnings outlook [10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - The system maintains a balanced distribution of "buy" and "sell" ratings, ensuring that only the top 20% of stocks are considered for superior earnings estimate revisions [9][10].